Jasreman Dhillon

Jasreman Dhillon

Auto-generated profile, based on publicly available information

Jasreman Dhillon

H. Lee Moffitt Cancer center and research Institute 8 Tampa, FL

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Roger LiRoger Li
Roger Li
NVNancy Y. Villa
Nancy Y. Villa
XYXiaoqing Yu
Xiaoqing Yu
JJJoseph O. Johnson
Joseph O. Johnson
GBGustavo Borjas
Gustavo Borjas
JCJose R Conejo-Garcia
Jose R Conejo-Garcia

22 December 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
JJJi-Hak Jeong
Ji-Hak Jeong
SZShangwei Zhong
Shangwei Zhong
FLFuzhuo Li
Fuzhuo Li
CHChanghao Huang
Changhao Huang
XCXueyan Chen
Xueyan Chen
JLJun-Li Luo
Jun-Li Luo
Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa); although most patients initially respond to ADT, almost all cancers eventually develop castration-resistant PCa (CRPC). Currently, most research focuses on castration-resistant tumors, and the role of tumors in remission is almost completely ignored. Here, we report that odorant-binding protein (OBP2A) released from tumors in remission during ADT catches survival factors, such as CXCL15/IL8, to promote PCa cell androgen-independent growth and enhance the infiltration of myeloid-derived suppressor cells (MDSCs) into tumor microenvironment, leading to the emergence of castration resistance. OBP2A knockdown significantly inhibits CRPC and metastatic CRPC development and improves therapeutic efficacy of CTLA-4/PD-1 antibodies. Treatment with OBP2A-binding ligand α-pinene interrupts the function of OBP2A and suppresses CRPC development. Furthermore, α-pinene–conjugated doxorubicin/docetaxel can be specifically delivered to tumors, resulting in improved anticancer efficacy. Thus, our studies establish a novel concept for the emergence of PCa castration resistance and provide new therapeutic strategies for advanced PCa.

28 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Roger LiRoger Li
Roger Li
WSWade J. Sexton
Wade J. Sexton
JDJasreman Dhillon
Jasreman Dhillon
ABAnders Berglund
Anders Berglund
SNShreyas Uttam Naidu
Shreyas Uttam Naidu
JZJingsong Zhang
Jingsong Zhang
Purpose: Immune checkpoint blockade holds promise for treating bacillus Calmette-Guerin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC). In this phase II study, we investigated the safety and efficacy of durvalumab, a human IgG1 monoclonal antibody, against BCG-unresponsive carcinoma in situ (CIS). Patients and Methods: Patients with BCG-unresponsive CIS-containing NMIBC received durvalumab IV at 1,500 mg every 4 weeks for up to 12 months. The primary endpoint was complete response (CR) rate at month 6, defined by negative cystoscopy, urine cytology, and absence of high-grade recurrence on bladder mapping biopsy. The null hypothesis specified a CR rate of 18% and alternative hypothesis of 40%. According to the Simon two-stage design, if ≤3/13 patients achieved CR during stage 1, the trial is stopped due to futility. Results: Between March 8, 2017, and January 24, 2020, 17 patients were accrued whereas 4 withdrew from study treatment after bladder biopsy at month 3 was positive for CIS. Two of 17 (12%) achieved a CR at month 6, with duration of response of 10 and 18 months, respectively. A single grade 3 lipase elevation was attributed to durvalumab, and immune-related adverse events were observed in 7/17 (41%) patients. Only 1/17 patients had high programmed death-ligand 1 expression pretreatment. On RNA sequencing, complement activation genes were elevated posttreatment, along with enrichment of tumor-associated macrophage signature. Conclusions: Durvalumab monotherapy conferred minimal efficacy in treating BCG-unresponsive CIS of the bladder, with 6-month CR of 12%. Complement activation is a potential mechanism behind treatment resistance.

22 June 2020 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MKMahmoud I. Khalil
Mahmoud I. Khalil
MKMohamed H. Kamel
Mohamed H. Kamel
JDJasreman Dhillon
Jasreman Dhillon
VMViraj Master
Viraj Master
RDRodney Davis
Rodney Davis
Philippe SpiessPhilippe Spiess
Philippe Spiess

13 May 2025 in Histopathology
Verified
Journal Article
Open access
MNMahra Nourbakshs
Mahra Nourbakshs
LDLiping Du
Liping Du
AAAndres Martin Acosta
Andres Martin Acosta
RAReza Alaghehbandan
Reza Alaghehbandan
AAAli Amin
Ali Amin
GGGiovanna A Giannico
Giovanna A Giannico
Aims: Standardizing pathology reporting protocols through peer consensus review is critical for the best quality of care metrics. Reporting heterogeneity due to discrepancies among professional societies and practice patterns may lead to heterogeneous management and treatment approaches. This issue prompted a multi‐institutional survey of pathologists to address potential similarities or differences in trends and practice patterns in prostate pathology reporting worldwide.Methods and Results: A REDCap survey was distributed among 175 pathologists worldwide, recruited through invitations and social media. The response rate among invited pathologists was 83%. The practice locations were as follows: North America (USA, Canada, and Mexico, 62%), Europe (17%), Australia/New Zealand (3%), Central/South America (2%), Asia (13%), and Africa (2%). Most pathologists practiced for <5 years (28%). A genitourinary (GU) pathology fellowship was completed by 37%, 58% practiced in a subspecialized setting, and 43% in academia. Reporting includes (63%) or subtracts (37%) intervening benign tissue. Both Gleason score and Grade Groups (GG)s were reported by 96% of responders, whereas 94% report percent pattern 4 (%4). Aggregate grading and volume estimation in undesignated cores with different grades in the same jar are reported by 73% and 54% for systematic biopsies, and 83% and 62% for targeted biopsies, respectively. Cribriform morphology was reported by 81%. For presumed intraductal carcinoma (IDC), 89% use basal cell markers when isolated (iIDC), 82% with GG1 cancer, and 37% with ≥GG2. iIDC or IDC associated with GG1 or with ≥GG2 was not graded by 90%, 78%, and 70%, respectively. In radical prostatectomies, 90% report %4, but only 53% report it if the overall grade is ≥7. A tumour with Gleason 3 + 3 = 6 and <5% pattern 4 was graded as GG2 by 64%. A 5% pattern 4 or 5 as a secondary pattern. Grading was assigned based on the dominant nodule by 59%. Finally, reporting practices were significantly associated with demographic characteristics.Conclusions: Although most issues are agreed upon, significant discordance is identified among societies and pathologists in different practice settings. We hope this survey will serve as the basis for future studies and new collaborative approaches to more standardized reporting practices.

23 March 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
XLXiaoyin Li
Xiaoyin Li
SRSiddhartha Roy
Siddhartha Roy
JDJennifer Damonte
Jennifer Damonte
HPHyun Y. Park
Hyun Y. Park
AHAasha I. Hoogland
Aasha I. Hoogland
BGBrian D. Gonzalez
Brian D. Gonzalez
Background: Prostate cancer affects African American men disproportionately compared with men of other racial/ethnic groups. To identify biological bases for this health disparity, we sought to create a state-wide biobank of African American prostate cancer survivors in Florida. Methods: African American men diagnosed with prostate cancer between 2013 and 2017 and living in Florida at diagnosis were identified through the State of Florida's cancer registry. Individuals were approached via mail and telephone, assessed for eligibility, and asked for informed consent. χ2 and t tests were conducted to identify differences between eligible and reachable individuals (i.e., had valid contact information) versus consented participants. Results: Of the 5,960 eligible and reachable individuals, 3,904 were eligible and contacted at least once, and 578 consented [overall consent rate = 10% (578/5,960); adjusted consent rate = 15% (578/3,904)]. Statistically significant (Ps < 0.05) but small differences in demographic and clinical variables were observed. Consented participants were less likely to be older than 64 (35% vs. 41%) and less likely to have received radiotherapy (36% vs. 41%) and hormone therapy (16% vs. 21%), but more likely to have regional prostate cancer (13% vs. 11%) and have undergone surgery (44% vs. 39%). Consented participants did not differ from reachable individuals on other demographic and clinical factors (Ps > 0.05). Conclusions: Recruiting African American prostate cancer survivors to biobanking research through a cancer registry is feasible. However, the consent rate was low, and existing challenges limit consent and participation. Impact: Strategies for overcoming barriers to informed consent and increasing participation in biospecimen research are needed to address cancer disparities.